Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies

NCT02006485 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma

Interventions

DRUG: Ublituximab + TGR-1202
DRUG: Ublituximab + TGR-1202 + ibrutinib
DRUG: Ublituximab + TGR-1202 + bendamustine

Sponsor

TG Therapeutics, Inc.